Pharming Receives EU Approval for Rare Immunodeficiency Therapy

viernes, 27 de marzo de 2026, 12:12 pm ET1 min de lectura
PHAR--

Pharming Group announced that an expert panel of the European Medicines Agency has recommended marketing authorization for Joenja, a treatment for a rare form of immunodeficiency. The positive opinion supports Joenja's approval for marketing in the EU, pending final approval from the European Commission.

Pharming Receives EU Approval for Rare Immunodeficiency Therapy

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios